clonidine has been researched along with Cerebrovascular Disorders in 21 studies
Clonidine: An imidazoline sympatholytic agent that stimulates ALPHA-2 ADRENERGIC RECEPTORS and central IMIDAZOLINE RECEPTORS. It is commonly used in the management of HYPERTENSION.
clonidine (amino form) : A clonidine that is 4,5-dihydro-1H-imidazol-2-amine in which one of the amino hydrogens is replaced by a 2,6-dichlorophenyl group.
Cerebrovascular Disorders: A spectrum of pathological conditions of impaired blood flow in the brain. They can involve vessels (ARTERIES or VEINS) in the CEREBRUM, the CEREBELLUM, and the BRAIN STEM. Major categories include INTRACRANIAL ARTERIOVENOUS MALFORMATIONS; BRAIN ISCHEMIA; CEREBRAL HEMORRHAGE; and others.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Thirty patients with old post-stroke spastic hemiparesis took part in the investigation." | 1.29 | Mechanisms of tizanidine action on spasticity. ( Georgiev, D; Milanov, I, 1994) |
| "On the spastic side a reflex with prolonged latencies and durations, as well as with decreased amplitudes and thresholds of both reflex responses was found." | 1.28 | Flexor reflex for assessment of common interneurone activity in spasticity. ( Milanov, IG, 1992) |
| "Treatment with clonidine significantly slowed the rate of recovery (Kruskal-Wallis H = 8." | 1.28 | Clonidine impairs recovery of beam-walking after a sensorimotor cortex lesion in the rat. ( Davis, JN; Goldstein, LB, 1990) |
| "It is hypothesized that enlargement of berry aneurysms, the progression of cerebral atherosclerosis, and embolism from carotid lesions might all be decreased by the selection of antihypertensive agents which decrease blood velocity." | 1.26 | Effects of antihypertensive drugs on blood velocity: implications for prevention of cerebral vascular disease. ( Spence, JD, 1977) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 11 (52.38) | 18.7374 |
| 1990's | 9 (42.86) | 18.2507 |
| 2000's | 1 (4.76) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zhang, Y | 1 |
| Yamada, S | 1 |
| Ishima, T | 1 |
| Hayashi, M | 1 |
| Tomita, T | 1 |
| Hayashi, E | 1 |
| Ram, CV | 2 |
| Eninia, GI | 1 |
| Smeltere, ES | 1 |
| Godlevska, MA | 1 |
| Uzulinia, IP | 1 |
| Zamotaev, IP | 1 |
| Abramova, VG | 1 |
| Stankovskaia, IM | 1 |
| Sattar, MA | 1 |
| Johns, EJ | 1 |
| Prattichizzo, FA | 1 |
| Galetta, F | 1 |
| Bonechi, I | 1 |
| Giusti, C | 1 |
| Milanov, I | 1 |
| Georgiev, D | 1 |
| Goldberg-Stern, H | 1 |
| Atlas, D | 1 |
| Schwartz, L | 1 |
| Achiron, A | 1 |
| Ziv, I | 1 |
| Djaldetti, R | 1 |
| Zoldan, Y | 1 |
| Melamed, E | 1 |
| Lockette, W | 1 |
| Kirkland, K | 1 |
| Farrow, S | 1 |
| Medvedev, OS | 2 |
| Kunduzova, OR | 2 |
| Murashev, AN | 2 |
| Medvedeva, NA | 2 |
| Spence, JD | 1 |
| Zweifler, AJ | 1 |
| Esler, M | 1 |
| Milanov, IG | 1 |
| Goldstein, LB | 1 |
| Davis, JN | 1 |
| Medici, M | 1 |
| Pebet, M | 1 |
| Ciblis, D | 1 |
| Meese, RB | 1 |
| Regli, F | 1 |
| Bauer, GE | 2 |
| Raftos, J | 1 |
| Lewis, RG | 1 |
| Stokes, GS | 1 |
| Mitchell, AS | 1 |
| Young, AA | 1 |
| Maclachlan, I | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase I-II Clinical Trial to Determine the Safety of Clonidine in Infants With Hypoxic Ischemic Encephalopathy During Therapeutic Hypothermia[NCT01862250] | Phase 1/Phase 2 | 13 participants (Actual) | Interventional | 2013-10-03 | Completed | ||
| Study of the Effects on Motor Recovery of Early Post-stroke Spasticity Treatment: Double Blinded Comparison Between Botulinum Toxin and Baclofen.[NCT02462317] | Phase 4 | 184 participants (Actual) | Interventional | 2015-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Intravenous morphine (mg/kg) was given. The standard dose is 0.05 mg/kg per dose (NCT01862250)
Timeframe: Up to 2 days
| Intervention | mg/kg (Median) |
|---|---|
| Clonidine Infants With HIE | 0.02 |
Babies were assessed after administration of clonidine for the presence or absence of shivering. (NCT01862250)
Timeframe: 48hrs
| Intervention | Participants (Count of Participants) |
|---|---|
| Clonidine Infants With HIE | 0 |
"Trough clonidine blood levels were measured after 4-7 doses of clonidine were given intravenously with a dosing interval of every 8 hrs. Mean and standard deviation (SD) of the number of doses given prior to levels being drawn was 5.3 (mean) and 0.37 (SD).~Time after last dose before measurement was 9hrs (mean) and 2.7hrs (SD)." (NCT01862250)
Timeframe: 3 days
| Intervention | ng/ml (Median) |
|---|---|
| Clonidine Infants With HIE | 0.6 |
Following 2 hours of therapeutic hypothermia, the temperature of the thermo-blanket is adjusted up half degree per hour allowing passive rewarming until 36.5 degrees is reached (NCT01862250)
Timeframe: Beginning at 72 hours up to 12 hours
| Intervention | Hours (Median) |
|---|---|
| Clonidine Infants With HIE | 8.7 |
2 reviews available for clonidine and Cerebrovascular Disorders
| Article | Year |
|---|---|
Hypertensive crisis.
Topics: Antihypertensive Agents; Brain Diseases; Cerebrovascular Disorders; Clonidine; Coronary Disease; Dia | 1984 |
Hypertensive cardiovascular emergencies.
Topics: Antihypertensive Agents; Brain Diseases; Cerebrovascular Disorders; Clonidine; Coronary Disease; Dia | 1985 |
2 trials available for clonidine and Cerebrovascular Disorders
| Article | Year |
|---|---|
A double-blind, long-term study of tizanidine ('Sirdalud') in spasticity due to cerebrovascular lesions.
Topics: Adult; Aged; Baclofen; Cerebrovascular Disorders; Clinical Trials as Topic; Clonidine; Double-Blind | 1989 |
[Treatment of vascular headaches].
Topics: Adrenergic beta-Antagonists; Carbamazepine; Cerebrovascular Disorders; Clonidine; Ergotamine; Female | 1973 |
17 other studies available for clonidine and Cerebrovascular Disorders
| Article | Year |
|---|---|
Clonidine preconditioning decreases infarct size and improves neurological outcome from transient forebrain ischemia in the rat.
Topics: Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-2 Receptor Antagonists; Adrenergic alpha-Agon | 2004 |
Reduced alpha 2-adrenoceptor binding in lower brainstem of stroke-prone spontaneously hypertensive rats.
Topics: Adrenergic alpha-Agonists; Animals; Blood Pressure; Brain Stem; Cerebrovascular Disorders; Clonidine | 1984 |
[Characteristics of the action of gemiton, adelfan and dopegit on cerebral circulation in arterial hypertension].
Topics: Aged; Antihypertensive Agents; Cerebrovascular Circulation; Cerebrovascular Disorders; Chronic Disea | 1984 |
[Withdrawal syndrome in the treatment of arterial hypertension with clofelin].
Topics: Adult; Aged; Cerebrovascular Disorders; Clonidine; Humans; Hypertension; Male; Middle Aged; Substanc | 1983 |
Evidence for an alpha 1-adrenoceptor subtype mediating adrenergic vasoconstriction in Wistar normotensive and stroke-prone spontaneously hypertensive rat kidney.
Topics: Adrenergic alpha-Antagonists; Amlodipine; Animals; Cerebrovascular Disorders; Clonidine; Dose-Respon | 1994 |
[Therapy of arterial hypertension associated with acute stroke. Current trends and problems].
Topics: Acute Disease; Aged; Antihypertensive Agents; Blood Pressure Monitors; Cerebral Hemorrhage; Cerebrov | 1994 |
Mechanisms of tizanidine action on spasticity.
Topics: Adult; Aged; Cerebrovascular Disorders; Clonidine; Electromyography; Female; H-Reflex; Hemiplegia; H | 1994 |
Detection and measurement of an endogenous clonidine-displacing substance in human cerebrospinal fluid.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Binding, Competitive; Cerebrospinal Fluid Proteins; Cere | 1993 |
Alpha 2-adrenergic agonists increase cellular lactate efflux.
Topics: Adrenergic alpha-Agonists; Animals; Body Temperature Regulation; Cells, Cultured; Cerebrovascular Di | 1996 |
Chronopharmacological dependence of antihypertensive effects of the imidazoline-like drugs in stroke-prone spontaneously hypertensive rats.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Cerebrovascular Disorders; Circadian Rhythm; Cloni | 1998 |
Influence of sinoaortic barodenervation on the hypotensive effects of imidazoline-like drugs in stroke-prone spontaneously hypertensive rats.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Cerebrovascular Disorders; Circadian Rhythm; Cloni | 1999 |
Effects of antihypertensive drugs on blood velocity: implications for prevention of cerebral vascular disease.
Topics: Animals; Antihypertensive Agents; Blood Circulation; Blood Flow Velocity; Cerebrovascular Disorders; | 1977 |
Factors influencing the choice of antihypertensive agents.
Topics: Age Factors; Aldosterone; Cerebrovascular Disorders; Clonidine; Depression; Diabetes Complications; | 1976 |
Flexor reflex for assessment of common interneurone activity in spasticity.
Topics: Adult; Aged; Anti-Anxiety Agents; Baclofen; Benzodiazepines; Benzodiazepinones; Cerebrovascular Diso | 1992 |
Clonidine impairs recovery of beam-walking after a sensorimotor cortex lesion in the rat.
Topics: Animals; Brain Injuries; Cerebral Cortex; Cerebrovascular Disorders; Clonidine; Disease Models, Anim | 1990 |
Treatment of hypertension in the elderly.
Topics: Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Cerebrovascular Disorders; Clonidine; Di | 1974 |
Clonidine in the treatment of severe hypertension.
Topics: Adult; Anesthesia, General; Cerebrovascular Disorders; Clonidine; Coronary Disease; Depression; Huma | 1973 |